| ALX-210-948-C100 | 100 µg | 359.00 USD |  |
||
| Do you need bulk/larger quantities? | |||||
| Alternative Name: | FAM3C, Interleukin-like EMT inducer |
| Host: | Rabbit |
| Immunogen: | Recombinant mouse ILEI (aa 25-227). |
| UniProt ID: | Q91VU0 |
| Source: | Purified from rabbit serum. |
| Species reactivity: | Human, Mouse |
| Applications: | IP, WB |
| Recommended Dilutions/Conditions: | Immunoprecipitation (1:200) Western Blot (1:1,000) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
| Purity Detail: | Protein A-affinity purified. |
| Formulation: | Liquid. In PBS containing 0.02% sodium azide. |
| Use/Stability: | Stable for at least 1 year after receipt when stored at -20°C. |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
| Shipping: | Shipped on Blue Ice |
| Short Term Storage: | +4°C |
| Long Term Storage: | -20°C |
| Scientific Background: | In 2006, T. Waerner, et al. characterized ILEI as a key player in both epithelial to mesenchymal transition and late-stage carcinoma progression. EMT is a process that involves changes in gene expression, cytoskeleton organization, cell adhesion, and extracellular matrix composition. This process is important during tissue formation and organogenesis, but also during cancer progression, metastasis and chronic inflammation. ILEI is overexpressed and/or altered in intracellular localization in multiple human tumors, an event strongly correlated to invasion/EMT, metastasis formation, and survival in human colon and breast cancer. |
| Regulatory Status: | RUO - Research Use Only |
